Company intelligence / Profile preview

Mnemo Therapeutics

Paris, Île-de-France, Francemnemo-tx.com ↗
Ownership
Private
Employees
~125
Development stage
Other
01

Overview

No detailed clinical trial results publicly disclosed yet; company is accelerating development with promising preclinical data around tumor specificity and improved CAR T persistence.

Therapeutic areas
OncologyHematology
Modalities
Cell therapies including CAR T cell therapyT cell engagers (TCE)Antibody-drug conjugates (ADC)Vaccines
Industry
Biotech
02

Drug pipeline

1 asset

SUV39H1-inactivated CAR T cells

Preclinical
03

Partnerships

Institut CurieMemorial Sloan Kettering Cancer Center

Beyond the preview

Go deeper on Mnemo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mnemo Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call